

## Supplementary Material

### Degradation Profiling of Nardosinone at High Temperature, and in Simulated Gastric and Intestinal Fluids

Bian-Xia Xue<sup>a,†</sup>, Tian-Tian Yang<sup>a,†</sup>, Ru-Shang He<sup>a,†</sup>, Wen-Ke Gao<sup>a</sup>, Jia-Xin Lai<sup>a</sup>, Si-Xia Liu<sup>a</sup>, Cong-Yan Duan<sup>a</sup>, Shao-Xia Wang<sup>a</sup>, Hui-Juan Yu<sup>a</sup>, Wen-Zhi Yang<sup>a</sup>, Li-Hua Zhang<sup>a,\*</sup>, Qi-Long Wang<sup>a,\*</sup>, Hong-Hua Wu<sup>a,b,\*</sup>

<sup>a</sup> National Key Laboratory of Chinese Medicine Modernization, State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, West Area, Tuanbo New Town, Jinghai District, Tianjin 301617, China

<sup>b</sup> Tianjin Key Laboratory of Therapeutic Substance of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, West Area, Tuanbo New Town, Jinghai District, Tianjin 301617, China

---

**\* Corresponding authors:**

Li-Hua Zhang, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, West Area, Tuanbo New Town, Jinghai District, Tianjin, 301617, China  
Tel./fax: +86-022-59791830  
E-mail address: zhanglihua200061@163.com (L.-H. Zhang).


Qi-Long Wang, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, West Area, Tuanbo New Town, Jinghai District, Tianjin, 301617, China  
E-mail address: wangqilong\_00@tjutcm.edu.cn (Q.-L. Wang).  
ORCID: <https://orcid.org/0000-0002-4375-991X>

Hong-Hua Wu, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, West Area, Tuanbo New Town, Jinghai District, Tianjin, 301617, China  
Tel./fax: +86-022-59791833  
E-mail address: wuhonghua2011@tjutcm.edu.cn (H.-H. Wu).  
ORCID: <https://orcid.org/0000-0002-3089-4282>.


**† Co-first authors:**

B. X. Xue, T.-T. Yang and R.-S. He contributed equally to this work and should be considered co-first authors


<b>Table of Contents</b>	<b>Page</b>
<b>Figure S1</b> Structures ( <b>a</b> ) and optimized conformers ( <b>b</b> ) for the ECD calculation of 2–deoxokanshone M	2
<b>Figure S2</b> Structures ( <b>a</b> ) and optimized conformers ( <b>b</b> ) for the ECD calculation of 2–deoxokanshone L	2
<b>Figure S3</b> Representative UPLC chromatograms of 2–deoxokanshone M incubated in HT and SGF–A	3
<b>Figure S4</b> The stability of 2–deoxokanshone M in boiling water for 2 h. ( <b>a</b> ) Stacked UPLC chromatograms of 2–deoxokanshone M in boiling water for 0, 30, 60, and 120 min ( <b>b</b> ); the line graph of the relative content change of nardosinone and 2–deoxokanshone M in boiling water	3
<b>Figure S5</b> $^1\text{H}$ NMR (600 MHz, CD <sub>3</sub> OD) spectrum of 2–deoxokanshone M	4
<b>Figure S6</b> $^{13}\text{C}$ NMR (150 MHz, CD <sub>3</sub> OD) spectrum of 2–deoxokanshone M	4
<b>Figure S7</b> $^1\text{H}$ NMR (600 MHz, CD <sub>3</sub> OD) spectrum of the reaction mixture of 2–deoxokanshone M in 50% MeOH at 80°C for 48 h	5
<b>Figure S8</b> Representative UPLC chromatograms of nardosinone incubated in SGF ( <b>a</b> ), SGF–A ( <b>b</b> ) and SGF–B ( <b>c</b> )	6
<b>Figure S9</b> The degradation rate and dynamic variations of nardosinone and degradation products under three different conditions for 108 h. ( <b>a</b> ) Degradation percent of nardosinone in three conditions; time-concentration curves of nardosinone and its main degradation products in SGF ( <b>b</b> ), SGF–A ( <b>c</b> ) and SGF–B ( <b>d</b> )	6
<b>Figure S10</b> Mass spectrum ion fragment of desoxo-narchinol A	7
<b>Figure S11</b> Mass spectrum ion fragment of 2–deoxokanshone L	7
<b>Figure S12</b> Mass spectrum ion fragment of nardosinonediol	8
<b>Figure S13</b> Mass spectrum ion fragment of isonardosinone	8
<b>Figure S14</b> Mass spectrum ion fragment of 2–deoxokanshone M	9
<b>Figure S15</b> Mass spectrometry fragmentation pathway of desoxo-narchinol A (positive ion mode)	10
<b>Figure S16</b> Mass spectrometry fragmentation pathway of 2–deoxokanshone L (positive ion mode)	11
<b>Figure S17</b> Mass spectrometry fragmentation pathway of nardosinonediol (positive ion mode)	12
<b>Figure S18</b> Mass spectrometry fragmentation pathway of isonardosinone (positive ion mode)	13
<b>Figure S19</b> Mass spectrometry fragmentation pathway of 2–deoxokanshone M (positive ion mode)	14
<b>Figure S20</b> The separation process diagram of nardosinone	15
<b>Table S1</b> Characterization of nardosinone and its degradation products in three different conditions by using UHPLC-DAD/ESI–Q–TOF MS	16
<b>Table S2</b> The detailed parameters of the NMR measurements	19




**Figure S1** Structures **(a)** and optimized conformers **(b)** for the ECD calculation of 2–deoxokanshone M




**Figure S2** Structures **(a)** and optimized conformers **(b)** for the ECD calculation of 2–deoxokanshone L




**Figure S3** Representative UPLC chromatograms of 2-deoxokanshone M incubated in HT and SGF-A




**Figure S4** The stability of 2-deoxokanshone M in boiling water for 2 h. (a) Stacked UPLC chromatograms of 2-deoxokanshone M in boiling water for 0, 30, 60, and 120 min; (b) the line graph of the relative content change of nardosinone and 2-deoxokanshone M in boiling water




**Figure S5**  $^1\text{H}$  NMR (600 MHz,  $\text{CD}_3\text{OD}$ ) spectrum of 2-deoxokanshone M




**Figure S6**  $^{13}\text{C}$  NMR (150 MHz,  $\text{CD}_3\text{OD}$ ) spectrum of 2-deoxokanshone M




**Figure S7**  $^1\text{H}$  NMR (600 MHz,  $\text{CD}_3\text{OD}$ ) spectrum of the reaction mixture of 2-deoxokanshone M in 50% MeOH at  $80^\circ\text{C}$  for 48 h




**Figure S8** Representative UPLC chromatograms of nardosinone incubated in SGF  
**(a)**, SGF–A **(b)** and SGF–B **(c)**




**Figure S9** The degradation rate and dynamic variations of nardosinone and degradation products under three different conditions for 108 h. **(a)** Degradation percent of nardosinone in three conditions; time-concentration curves of nardosinone and its main degradation products in SGF **(b)**, SGF–A **(c)**, and SGF–B **(d)**




**Figure S10** Mass spectrum ion fragment of desoxo-narchinol A



**Figure S11** Mass spectrum ion fragment of 2-deoxokanshone L



**Figure S12** Mass spectrum ion fragment of nardosinonediol



**Figure S13** Mass spectrum ion fragment of isonardosinone







Figure S14 Mass spectrum ion fragment of 2-deoxokanshone M




**Figure S15** Mass spectrometry fragmentation pathway of desoxo-narchinol A (positive ion mode)




**Figure S16** Mass spectrometry fragmentation pathway of 2-deoxokanshone L (positive ion mode)




**Figure S17** Mass spectrometry fragmentation pathway of nardosinonediol (positive ion mode)



**Figure S18** Mass spectrometry fragmentation pathway of isonardosinone (positive ion mode)



**Figure S19** Mass spectrometry fragmentation pathway of 2-deoxokanshone M (positive ion mode)



**Figure S20** The separation process diagram of nardosinone

**Table S1** Characterization of nardosinone and its degradation products in three different conditions by using UHPLC–DAD/ESI–Q–TOF MS

Identification	RT (min)	Formula	Molecular weight	Mass ion (MS)	Fragments	Source
Desoxo-narchinol A ( <b>2</b> )	8.22	C <sub>12</sub> H <sub>16</sub> O <sub>2</sub>	192.1150	193.1239 [M+H] <sup>+</sup>	175.1117 [M+H-H <sub>2</sub> O] <sup>+</sup> 151.1112 [M+H-C <sub>3</sub> H <sub>6</sub> ] <sup>+</sup> 147.0797 [M+H-H <sub>2</sub> O-CO] <sup>+</sup> 133.1010 [M+H-H <sub>2</sub> O-CO-CH <sub>2</sub> ] <sup>+</sup> ; [M+H-H <sub>2</sub> O-C <sub>3</sub> H <sub>6</sub> ] <sup>+</sup> 123.0796 [M+H-C <sub>3</sub> H <sub>6</sub> -CO] <sup>+</sup>	HT; SGF; SGF-A; SGF-B; SIF
2-Deoxokanshone L ( <b>3</b> )	11.86	C <sub>15</sub> H <sub>22</sub> O <sub>3</sub>	250.1569	251.1646 [M+H] <sup>+</sup>	233.1643 [M+H-H <sub>2</sub> O] <sup>+</sup> 205.1589 [M+H-H <sub>2</sub> O-CO] <sup>+</sup> 193.1241 [M+H-H <sub>2</sub> O-C <sub>3</sub> H <sub>4</sub> ] <sup>+</sup> 191.1068 [M+H-H <sub>2</sub> O-C <sub>3</sub> H <sub>6</sub> ] <sup>+</sup> 177.0911 [M+H-H <sub>2</sub> O-CO-CO] <sup>+</sup> ; [M+H-H <sub>2</sub> O-C <sub>3</sub> H <sub>6</sub> -CH <sub>2</sub> ] <sup>+</sup> 163.0758 [M+H-H <sub>2</sub> O-CO-C <sub>3</sub> H <sub>6</sub> ] <sup>+</sup> ; 149.0962 [M+H-H <sub>2</sub> O-C <sub>3</sub> H <sub>6</sub> -CO-CH <sub>2</sub> ] <sup>+</sup> ; 135.0809 [M+H-H <sub>2</sub> O-CO-CO-C <sub>3</sub> H <sub>6</sub> ] <sup>+</sup> ; 123.0444 [M+H-H <sub>2</sub> O-CO-C <sub>3</sub> H <sub>6</sub> -C <sub>3</sub> H <sub>4</sub> ] <sup>+</sup> 121.0650 [M+H-H <sub>2</sub> O-CO-CO-C <sub>3</sub> H <sub>6</sub> -CH <sub>2</sub> ] <sup>+</sup> ; 109.1015 [M+H-H <sub>2</sub> O-C <sub>3</sub> H <sub>6</sub> -CH <sub>2</sub> -CO-C <sub>3</sub> H <sub>4</sub> ] <sup>+</sup> ;	HT; SGF; SGF-A; SGF-B; SIF
Nardosinonediol	14.33	C <sub>15</sub> H <sub>24</sub> O <sub>3</sub>	252.1725	235.1694 [M+H-H <sub>2</sub> O] <sup>+</sup>	217.1585 [M+H-H <sub>2</sub> O-H <sub>2</sub> O] <sup>+</sup> 177.1258 [M+H-H <sub>2</sub> O-H <sub>2</sub> O-C <sub>3</sub> H <sub>4</sub> ] <sup>+</sup> 149.0960 [M+H-H <sub>2</sub> O-H <sub>2</sub> O-C <sub>3</sub> H <sub>4</sub> -CO] <sup>+</sup>	SIF

					135.0805 [M+H-H <sub>2</sub> O-H <sub>2</sub> O-C <sub>3</sub> H <sub>4</sub> -C <sub>3</sub> H <sub>6</sub> ] <sup>+</sup> ; [M+H-H <sub>2</sub> O-H <sub>2</sub> O-C <sub>3</sub> H <sub>4</sub> -CO-CH <sub>2</sub> ] <sup>+</sup> 121.0645 [M+H-H <sub>2</sub> O-H <sub>2</sub> O-C <sub>3</sub> H <sub>4</sub> -C <sub>3</sub> H <sub>6</sub> -CH <sub>2</sub> ] <sup>+</sup> 107.0852 [M+H-H <sub>2</sub> O-H <sub>2</sub> O-C <sub>3</sub> H <sub>4</sub> -C <sub>3</sub> H <sub>6</sub> -CO] <sup>+</sup> ; [M+H-H <sub>2</sub> O-H <sub>2</sub> O-C <sub>3</sub> H <sub>4</sub> -CO-CH <sub>2</sub> -C <sub>2</sub> H <sub>4</sub> ] <sup>+</sup>	
Isonardosinone ( <b>4</b> )	17.80	C <sub>15</sub> H <sub>22</sub> O <sub>3</sub>	250.1569	251.1639 [M+H] <sup>+</sup>	233.1540 [M+H-H <sub>2</sub> O] <sup>+</sup> 215.1431 [M+H-H <sub>2</sub> O-H <sub>2</sub> O] <sup>+</sup> 205.1588 [M+H-H <sub>2</sub> O-CO] <sup>+</sup> 187.1477 [M+H-H <sub>2</sub> O-H <sub>2</sub> O-CO] <sup>+</sup> 175.1113 [M+H-H <sub>2</sub> O-H <sub>2</sub> O-C <sub>3</sub> H <sub>4</sub> ] <sup>+</sup> 173.0956 [M+H-H <sub>2</sub> O-H <sub>2</sub> O-C <sub>3</sub> H <sub>6</sub> ] <sup>+</sup> 163.1111 [M+H-H <sub>2</sub> O-CO-C <sub>3</sub> H <sub>6</sub> ] <sup>+</sup> 135.0803 [M+H-H <sub>2</sub> O-CO-C <sub>3</sub> H <sub>6</sub> -CO] <sup>+</sup> 133.1006 [M+H-H <sub>2</sub> O-H <sub>2</sub> O-C <sub>3</sub> H <sub>6</sub> -C <sub>3</sub> H <sub>4</sub> ] <sup>+</sup> 105.0697 [M+H-H <sub>2</sub> O-H <sub>2</sub> O-C <sub>3</sub> H <sub>6</sub> -C <sub>3</sub> H <sub>4</sub> -CO] <sup>+</sup>	HT; SGF-B; SIF
2-Deoxokanshone M ( <b>1</b> )	18.94	C <sub>12</sub> H <sub>16</sub> O <sub>2</sub>	192.1150	193.1226 [M+H] <sup>+</sup> ; 385.2404 [2M+H] <sup>+</sup>	179.1013 [M+H-CH <sub>2</sub> ] <sup>+</sup> 175.1122 [M+H-H <sub>2</sub> O] <sup>+</sup> 177.0904 [M+H-CH <sub>4</sub> ] <sup>+</sup> 163.0754 [M+H-CH <sub>2</sub> -CH <sub>4</sub> ] <sup>+</sup> ; [M+H-CH <sub>4</sub> -CH <sub>2</sub> ] <sup>+</sup> 151.0753 [M+H-C <sub>3</sub> H <sub>6</sub> ] <sup>+</sup> 149.0596 [M+H-CH <sub>4</sub> -CO] <sup>+</sup> 135.0805 [M+H-CH <sub>2</sub> -CH <sub>4</sub> -CO] <sup>+</sup> ; [M+H-CH <sub>4</sub> -CO-CH <sub>2</sub> ] <sup>+</sup> 123.0440 [M+H-C <sub>3</sub> H <sub>6</sub> -CO] <sup>+</sup>	HT; SGF; SGF-A; SGF-B

Nardosinone ( <b>5</b> )	28.12	$C_{15}H_{22}O_3$	250.1569	251.1646	121.0646 [M+H-CH <sub>4</sub> -CO-CO] <sup>+</sup>	—
					109.1009 [M+H-C <sub>3</sub> H <sub>6</sub> -CO-CH <sub>2</sub> ] <sup>+</sup>	
					107.0854 [M+H-CH <sub>4</sub> - CO-CO-CH <sub>2</sub> ] <sup>+</sup> ; [M+H-CH <sub>4</sub> -CO-C <sub>3</sub> H <sub>6</sub> ] <sup>+</sup>	
					233.1542 [M+H-H <sub>2</sub> O] <sup>+</sup>	
				[M+H] <sup>+</sup>	219.1372 [M+H-H <sub>2</sub> O-CH <sub>2</sub> ] <sup>+</sup>	
					215.1430 [M+H-H <sub>2</sub> O-H <sub>2</sub> O] <sup>+</sup>	
					205.1587 [M+H-H <sub>2</sub> O-CO] <sup>+</sup>	
					193.1226 [M+H-C <sub>3</sub> H <sub>4</sub> ] <sup>+</sup>	
					191.1429 [M+H-H <sub>2</sub> O-C <sub>3</sub> H <sub>6</sub> ] <sup>+</sup> ; [M+H-H <sub>2</sub> O-CH <sub>2</sub> -CO] <sup>+</sup>	
					177.0905 [M+H-H <sub>2</sub> O-C <sub>3</sub> H <sub>6</sub> -CH <sub>2</sub> ] <sup>+</sup> ; [M+H-H <sub>2</sub> O-CH <sub>2</sub> -CO-CH <sub>2</sub> ] <sup>+</sup> ; [M+H-H <sub>2</sub> O-CO-CO] <sup>+</sup>	
					175.1121 [M+H-C <sub>3</sub> H <sub>4</sub> -H <sub>2</sub> O] <sup>+</sup>	
					163.0750 [M+H-H <sub>2</sub> O-C <sub>3</sub> H <sub>6</sub> -CO] <sup>+</sup>	
					149.0956 [M+H-H <sub>2</sub> O-CH <sub>2</sub> -CO-CH <sub>2</sub> -C <sub>2</sub> H <sub>4</sub> ] <sup>+</sup> ;	
					[M+H-H <sub>2</sub> O-CH <sub>2</sub> -CO-C <sub>3</sub> H <sub>6</sub> ] <sup>+</sup>	
					135.0801 [M+H-H <sub>2</sub> O-CO-CO-CH <sub>2</sub> -C <sub>2</sub> H <sub>4</sub> ] <sup>+</sup>	
					123.0440 [M+H-H <sub>2</sub> O-CO-C <sub>3</sub> H <sub>6</sub> -C <sub>3</sub> H <sub>4</sub> ] <sup>+</sup>	
					109.1010 [M+H-H <sub>2</sub> O-CH <sub>2</sub> -CO-CH <sub>2</sub> -C <sub>2</sub> H <sub>4</sub> -C <sub>3</sub> H <sub>4</sub> ] <sup>+</sup> ;	
					[M+H-H <sub>2</sub> O-CH <sub>2</sub> -CO-C <sub>3</sub> H <sub>6</sub> -C <sub>3</sub> H <sub>4</sub> ] <sup>+</sup>	

**Table S2** The detailed parameters of the NMR measurements

Name	<sup>1</sup> H-NMR	<sup>13</sup> C-NMR	HSQC	HMBC	<sup>1</sup> H- <sup>1</sup> H COSY
Number of Scans (NS)	16	2838	16	32	16
Receiver Gain (RG)	31.78	55.56	188.54	188.54	188.54
Relaxation Delay (RD/D1)	1.0 s	2.0 s	1.5 s	1.5 s	2.0 s
Spectral Width (SWH)	12019.23 Hz	36231.9 Hz	12019.23 Hz, 36231.9 Hz	12019.23 Hz, 36231.9 Hz	12019.23 Hz, 11990.4 Hz
Acquisition Time (AQ)	2.7263 s	0.9044 s	0.0573 s	0.1704 s	0.0852 s
Spectrometer Frequency (SF)	600.20 MHz	150.95 MHz	600.20 MHz, 150.94 MHz	600.20 MHz, 150.94 MHz	600.21 MHz, 600.21 MHz
Pulse Width (P1)	9.23 $\mu$ s	10 $\mu$ s	9.23 $\mu$ s, 10 $\mu$ s	9.23 $\mu$ s, 10 $\mu$ s	9.23 $\mu$ s
Line broadening (LB)	0.3 Hz	1 Hz	0 Hz	0 Hz	0 Hz
Nucleus for channel (NUC1)	1 H	13 C	1 H, 13 C	1 H, 13 C	1 H, 1 H
Time domain size (TD)	65536	65536	1024	4096	2048
Number of dummy scans (DS)	0	0	16	16	16
Dwell time (DW)	41.6 $\mu$ s	13.8 $\mu$ s	56 $\mu$ s	41.6 $\mu$ s	41.6 $\mu$ s
Pre-scan-delay (DE)	10 $\mu$ s	18.0 $\mu$ s	10 $\mu$ s	10 $\mu$ s	10 $\mu$ s
PLW1	25.4480 W	24.194 W	25.4480 W, 24.194 W	25.4480 W, 24.194 W	25.4480 W
SI	65536	65536	1024, 1024	4096, 1024	1024, 1024
FID resolution (FIDRES)	0.367 Hz	1.106 Hz	17.439 Hz	5.859 Hz	11.738 Hz
PC	1	1.4	1.4	1.4	1.4